Global revenues of uveitis treatment market reached ~ 567 million in 2018, unveils the new research study by Persistence Market Research (PMR). According to the report, the uveitis treatment market is estimated to grow by ~6% CAGR in 2029, primarily attributed to rising R&D activities in the field of ophthalmology, increasing number of clinical trials for eye inflammation disorders treatment, increase in the investment in molecular biology, growing cases of infectious diseases, and increase in prevalence of uveitis.
The corticosteroids market is increasing a great deal of footing in the treatment landscape, as it has been the primary choice of medication for uveitis treatment by ophthalmologists. As corticosteroids are inexpensive, potent, and act fast, it has been used as a first line of therapy for patients with non-infectious ocular inflammatory diseases.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4430
- Allergan, Inc.
- Novartis AG
- Bausch Health Inc.
- AbbVie Inc.
- Eyegate Pharmaceuticals, Inc.
- Alimera Science Inc.
- EyePoint Pharmaceuticals
- Santen Pharmaceuticals
Corticosteroids may be administered either topically, systemically or periocular injections. The antibiotics treatment type segment is expected to be the fastest growing segment in the uveitis treatment market during the forecast period, owing to rise in infectious ocular disorders globally.
Monoclonal antibodies in uveitis treatment is also expected to emerge as the most preferred treatment type for patients globally, during the forecast period.
According to the report, in 2018 corticosteroids, monoclonal antibodies, and antibiotics constitute more than 50% of the total market revenue in the uveitis treatment market. Anterior uveitis is the most common form of uveitis constituting 75% of all cases of uveitis with annual incidence, 12 per 100,000.
It is a prominent segment among the uveitis treatment markets diseases type which represents ~57% share of total market.
Infectious etiologies represent between 15–20% of all instances of uveitis in certain part of the United States, and likely represents a substantially more critical extent of uveitis around the world. Infectious uveitis holds a strong market share ~87% of the total uveitis treatment market due to growing cases associated with certain form of bacterial, viral, fungal, helminthic, and parasitic uveitis.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4430
Emerging Therapies for Uveitis Treatment to Create Opportunities for Key Market Players
According to the PMR report, most ophthalmologists depend heavily on corticosteroids in uveitis treatment. But repeated use of corticosteroids in long term result in eye related complications.
Adjuvant treatment comprising cycloplegics, newer non–steroidal anti-inflammatory agents, and anti-vascular endothelial growth factor (anti-VEGF) therapy are used in uveitis treatment.
In case of anterior uveitis, periocular corticoids, and unilateral intermediate, treatment is effective when rapidly administered along with anti-inflammatory drug at high concentration. Adjuvant immunosuppressors have often been utilized nowadays, which indicated better outcomes in the past.
Ongoing advances in local corticosteroids delivery and outside of the conventional injectable course have opened new opportunities for manufacturers for uveitis treatment and as an option for patients who experienced unilateral diseases, or the ones having an aversion to systemic medications.
The new and running primary trend in the uveitis treatment market is the use of local steroid implants, that are proving out to be significantly accepted for drug delivery in case of noninfectious posterior uveitis.
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Persistence Market Research
Address – 305 Broadway, 7th Floor New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – email@example.com